Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.

Fenwick SW, Toogood GJ, Lodge JP, Hull MA.

Gastroenterology. 2003 Sep;125(3):716-29.

PMID:
12949718
2.
3.

Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.

Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G.

Gastroenterology. 2002 Jul;123(1):60-7.

PMID:
12105834
4.

The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.

Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T, Kitajima M.

Anticancer Res. 2003 Jan-Feb;23(1A):245-9.

PMID:
12680220
5.

Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.

Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P, Borel Rinkes IH.

Clin Cancer Res. 2005 Jan 1;11(1):41-8.

6.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.

J Rheumatol. 1999 Nov;26(11):2438-47.

PMID:
10555907
7.

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ.

Gastroenterology. 2001 Mar;120(4):867-73.

PMID:
11231941
8.

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.

Spieth K, Kaufmann R, Gille J.

Cancer Chemother Pharmacol. 2003 Nov;52(5):377-82. Epub 2003 Jul 22.

PMID:
12879280
9.
10.

COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.

Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kandzari S.

J Surg Res. 2004 Jun 15;119(2):138-42.

PMID:
15145695
11.

Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM.

Cancer Res. 2003 Feb 1;63(3):586-92.

12.

Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.

Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicz M, Hartwich A, Rehfeld JF, Hahn EG.

Dig Dis Sci. 2003 Oct;48(10):2005-17.

PMID:
14627349
13.

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL.

Ann Intern Med. 2000 Jul 4;133(1):1-9.

PMID:
10877734
14.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
15.
16.

NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.

Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM.

J Am Coll Surg. 2004 Sep;199(3):428-35.

PMID:
15325613
17.

Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery.

Bekker A, Cooper PR, Frempong-Boadu A, Babu R, Errico T, Lebovits A.

Neurosurgery. 2002 May;50(5):1053-7; discussion 1057-8.

PMID:
11950408
18.

Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry.

Jackson ID, Heidemann BH, Wilson J, Power I, Brown RD.

Br J Anaesth. 2004 May;92(5):675-80. Epub 2004 Mar 19.

PMID:
15033894
19.

Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).

Vona-Davis L, Riggs DR, Jackson BJ, McFadden DW.

J Surg Res. 2004 Jun 15;119(2):143-8. Erratum in: J Surg Res. 2004 Aug;120(2):326.

PMID:
15145696
20.

Supplemental Content

Support Center